Aim: To compare the short-term outcomes and effect on early establishment of enteral feeds in stable extremely preterm infants when managed with and without umbilical catheters.
Australia. Email: dr.abhijatabnave@gmail.com Aim: To compare the short-term outcomes and effect on early establishment of enteral feeds in stable extremely preterm infants when managed with and without umbilical catheters.
Methods: A single centre retrospective cohort study (January 2010-October 2017) assessing infants born <28 weeks, utilising prospectively collected time/date stamped, audited data from a real-time electronic database. The infants were divided into 2 groups as per primary mode of CVL access (UVC vs PICC) and were matched step wise with respect to gestational age, birth year and BW.
Results: A total of 114 infants included with 57 infants in each group. When compared to PICC group the UVC group had a shorter duration of 1 st CVL (UVC) (4 days vs 14 days, P < 0.001) with higher incidence of 2 nd CVL insertion (91% vs 24%, P value <0.001). UVC group had a median of 2 CVLs inserted compared with 1 CVL in PICC group (P < 0.001). The UVC Group had a higher incidence of inotropes use (28% vs 1.75%, P < 0.001), IVH (12.2 % vs 0%, P < 0.006) and an increasing trend of death (17.5 % vs 3%, P = 0.152).CLABSI episodes and other outcomes were similar in both groups. The UVC group received a lesser amount of feeds at the end of the first week (20 mL/kg/kg/day vs 33 mL/kg/day, P < 0.004). Conclusions: UVC group had high incidence of CVLs insertion, inotropes use, IVH and also received lesser amount of feeds at 1 st week of age. A randomised control trial is needed to compare short terms outcomes using UVCs vs PICC.
CAUTION! THE HIDDEN DANGERS OF ANTENATAL CORTICOSTEROID ADMINISTRATION IN HELLP SYNDROME
Adams W 1* Calvert K 1 1 King Edward Memorial Hospital, Perth, Australia.
Email: loren.adams@health.wa.gov.au Background: HELLP syndrome (Haemolysis Elevated Liver enzymes, Low Platelets) is a potentially life-threatening variant of pre-eclampsia with a risk of iatrogenic prematurity. Clinicians have a low threshold for giving antenatal corticosteroids for fetal lung maturation in the setting of deteriorating HELLP. Corticosteroids have also been proposed as a maternal treatment in HELLP, but improvements in maternal outcomes have not been demonstrated and the current indication for this therapy remains primarily neonatal. We present a case where administration of steroids led to improvement in biochemical markers and masked worsening of the patient's condition with subsequent severe deterioration requiring urgent delivery.
Method: Consent was given by the patient to present her case.
Results: The results of the patient pre and post celestone showed initial improvement with subsequent precipitous decline. Platelets on the day of the 1st dose were 87, rising to 111 on day 2 and 197 on day 3. On day 4 the platelets fell to 42 and were 34 at the time of delivery on day 4. ALT showed an identical improvement followed by rapid deterioration.
Conclusions: Clinicians should not be falsely reassured by a temporary improvement in biochemical indices following corticosteroids administration in HELLP. Although the current indication for antenatal corticosteroids remains fatal, the therapy could have a temporary impact on the maternal clinical picture to a degree which cannot be confidently predicted. Vigilance is required to monitor biochemical and clinical decline and to act expeditiously in the event of sudden deterioration. Stage 2: Identifying outcomes that are important to parents and healthcare professionals
DEVELOPMENT OF A CORE OUTCOME SET AND IDENTIFICATION OF OUTCOME MEASUREMENT TOOLS TO IMPROVE CARE AND RESEARCH AFTER STILLBIRTH: ICHOOSE STUDY
We are recruiting 40 to 50 parents from the UK & Australia who have experienced a stillbirth to take part in face-to-face interview to investigate what their experiences have been. Outcomes will be identified by thematic analysis.
Stage 3: Determining the Core Outcome Set Parents, healthcare professionals and researchers will participate in a three-round online Delphi study to prioritise outcomes identified in stages 1 & 2. A consensus meeting with stakeholders will be held to determine the COS.
Stage 4: Determining how core outcomes should be measured An in-depth quality assessment of outcome measurement instruments will be take place on the COS.
Patient and public involvement: A dedicated iCHOOSE parent involvement group has been convened with 13 bereaved doi:10.1111/jpc.14407
